FDA Rejects New Indications for Coronary Artery Disease Drugs

Article

New drug applications for Zetia and Vytorin were for reducing the risk of cardiovascular events in patients with coronary artery disease.

Merck has received a complete response letter from the FDA regarding its supplemental new drug applications for ezetimibe (Zetia) and ezetimibe and simvastatin (Vytorin).

Merck hoped to expand the indications for Zetia and Vytorin so that they could be used for reducing the risk of cardiovascular events (eg, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary artery disease.

The supplemental new drug applications for Zetia and Vytorin included clinical trial data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial.

In a statement, Merck said it was reviewing the FDA’s complete response letter and would determine the next steps.

Zetia's effects on cardiovascular morbidity and mortality have not been determined.

Zetia and Vytorin are already approved to reduce elevated low-density lipoprotein cholesterol in patients with hyperlipidemia, alongside a healthy diet.

Related Videos
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.